
Niraparib Receives FDA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer
(May 4, 2020) On April 29th, the Food and Drug Administration approved niraparib (Zejula, GlaxoSmithKline) as a first-line maintenance treatment for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, … Continued